Safety Notices

From time to time notices relating to the safety and/or quality of medicinal products are published by the Health Products Regulatory Authority

These notices are classified under several priority related categories and may relate to human and veterinary medicines, or medical devices.   

The issues covered by these notices will range from quality defect information and medicinal product safety information through to updated information on the appropriate usage of medicines or devices.

Notices are categorised in accordance with their importance at time of publication.

The four notice categories are outlined as follows:

  • Advisory  -  Routine safety information            
  • Warning  -  Urgent safety information
  • Recall  -  Urgent safety information relating to a product recall
  • Publications  -  General safety information provided by the HPRA for publication via 3rd parties e.g. MIMS

The HPRA Drug Safety Newsletter is also published on a regular basis.

Date Title Type
12/03/2007 Zyvox (linezolid injection, tablets and oral suspension) - Important Safety Information from Pfizer as approved by the Irish Medicines Board 3rd Party Publications
07/03/2007 Avandia (rosiglitazone maleate) - Important Safety Information from GlaxoSmithKline as approved by the Irish Medicines Board 3rd Party Publications
07/03/2007 Raptiva (efalizumab) - Important Safety Information from Serono as approved by the Irish Medicines Board 3rd Party Publications
01/03/2007 Avonex, Betaferon and Rebif- Important Safety Information from Serono as approved by the Irish Medicines Board 3rd Party Publications
28/02/2007 Terbinafine for Oral Use 3rd Party Publications
04/01/2007 Rocephin (ceftriaxone) 1g and 2g powder for solution for injection or infusion and 1g powder and solvent for IM injection only - Important Safety Information from Roche as approved by the Irish Medicines Board 3rd Party Publications
31/12/2006 NON-SELECTIVE NON-STEROIDAL ANTI-INFLAMMATORY DRUGS 3rd Party Publications
12/12/2006 NovoRapid (insulin aspart) and Levemir (insulin detemir) - Important Safety Information from Novo Nordisk as approved from the Irish Medicines Board 3rd Party Publications
01/12/2006 Glivec (imatinib) - Important Safety Information from Novartis as approved by the Irish Medicines Board 3rd Party Publications
30/11/2006 ANGIOTENSIN CONVERTING ENZYME [ACE] INHIBITORS 3rd Party Publications